Register for free to
view the full innovation profile.
It results in potent inhibition of angiogenesis and tumorigenesis and it causes a marked decrease in tumour volume in a mouse xenograft model.
About
Description GFB-204 is a novel compound that binds PDGF and VEGF and prevents binding to their respective receptors, and subsequently suppresses downstream signalling pathways. GFB-204 is selective for PDGF and VEGF, and does not inhibit EGF, IGF-1 and FGF stimulation of Erk1/2, Akt, and STAT3. As shown in the figure, GFB-204 causes a marked decrease in tumour volume in a mouse xenograft model. Inhibition of VEGF and PDGF receptor binding with GFB-204 results in potent inhibition of angiogenesis and tumorigenesis. IND-enabling studies have been initiated for GFB-204 for AMD and cancer. Published/Issued Patents U.S. Patent No. 7,482,483 (link is external) U.S. Patent No. 7,718,700 (link is external) PCT App. Pub. No. WO2005072779